Novo Nordisk Navigates US Market Headwinds & Leadership Shift
Novo Nordisk faces slowing growth, fierce competition from Eli Lilly and copycats in the US, prompting a CEO change and strategic refocus.
/ 21 items
#NVO↓
Trump Admin Eyes Major GLP-1 Weight Loss Drug Coverage
The Trump administration is considering a five-year pilot program for Medicare & Medicaid to cover costly GLP-1 weight-loss drugs like Wegovy & Zepbound for millions, a significant policy shift.
Novo Nordisk Lowers 2025 Outlook, Names New CEO
Novo Nordisk cut its 2025 sales and profit forecast due to slower US Wegovy & Ozempic sales, hit by competition and compounded GLP-1s. Maziar Mike Doustdar is the new CEO.